Drug Trial Radar · NCT07915011
Investigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Renal Impairment
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
May 26, 2026
Primary completion
Nov 2026
Study completion Jan 2027
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is being conducted to compare the pharmacokinetics, safety of HSK31858 in subjects with mild, moderate, severe renal impairment and normal renal function.
Conditions
- Non-cystic Fibrosis Bronchiectasis (NCFBE)
Interventions
HSK31858 tabletsDrug
oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: Time Frame: Post-dose at day 1 to day 14
- AUC0-tTime frame: Time Frame: Post-dose at day 1 to day 14
- AUC0-∞Time frame: Time Frame: Post-dose at day 1 to day 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital Fudan University
Zhenzhou, Henan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.